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Simultaneous detection of Mycobacterium 
bovis and M. tuberculosis in an apparently 
immunocompetent patient
Mycobacterium tuberculosis remains the main cause 
of human tuberculosis (TB), with an unknown pro-
portion of cases caused by M. bovis. Here we describe 
a case of pulmonary TB caused by mixed infection as 
studied from sequential sputum sampling and isola-
tion of M. tuberculosis and M. bovis using a reverse 
dot blot (RDB) assay. 
In December 2010, a 68-year-old human immuno-
defi ciency virus negative male from the West Bank 
Palestinian territories was referred to the Palestinian 
Ministry of Health clinic with a history of cough, 
f ever and dyspnoea for 6 months. The purifi ed pro-
tein derivative skin test was negative; Ziehl Neelsen-
stained sputum smear was positive. 
Treatment with the Category I regimen was initi-
ated. Mycobacterial growth was observed after 9 weeks 
of incubation of the sputum sample. Polymerase 
chain reaction (PCR) targeting the insertion sequence 
(IS) 6110 of the M. tuberculosis complex was found 
positive.1 The isolate was further identifi ed as M. bo-
vis via multiplex-PCR as previously described.2 The 
patient’s travel history revealed a potential risk of ex-
posure to TB, as he has been working and living for 
12 years with workers from high TB prevalence coun-
tries where both M. tuberculosis and M. bovis are 
known to co-exist.3 
In June 2011, a second isolate was identifi ed as 
M. tuberculosis using the same methods as described 
above. At that point, treatment with the Category II 
regimen was initiated. For defi nitive identifi cation of 
the causative pathogen, DNA was extracted directly 
from the decontaminated sediment of the smear-
positive sputum samples taken at different dates. Three 
sputum samples along with the two isolates were 
tested by RDB assay, which included two amplifi ca-
tion reactions targeting short amplicons of IS6110 
and the oxyR gene. Three probes were selected: an 
M. tuberculosis complex-specifi c probe derived from 
IS6110,4 and two probes species-specifi c to M. tuber-
culosis and M. bovis, respectively, based on G/A tran-
sition of the oxyR gene.5 All sputum samples gave 
three hybridisation signals indicative of mixed infec-
tion with the two mycobacterial pathogens (Figure). 
Despite treatment, the patient remained smear-
positive, with progressive haemoptysis and weight loss 
(14 kg lost since diagnosis). In February 2012, the pa-
tient was transferred to a neighbouring country with 
suspected multidrug-resistant TB, but his condition de-
teriorated and he died before medical re-evaluation. 
We assume that the patient was co-infected with 
both pathogens and that at a given time one pathogen 
became masked by the other during disease progres-
sion. The most likely scenario is that mixed infection 
was caused by reactivation of latent infection, refl ect-
ing his travel history. The delay in the fi nal diagnosis 
of the causative pathogen resulted in inadequate treat-
ment, particularly the use of pyrazinamide in the fi rst 
2 months of treatment and in the Category II regimen, 
as M. bovis is naturally resistant to pyrazinamide. 
The RDB assay of sequential sputum samples con-
fi rmed the dual infection of both pathogens, as they 
were found to be present simultaneously in a single 
sample. Mixed infection with these two closely re-
lated pathogens was detected by isolation and iden-
tifi cation of viable bacilli of both species from two 
different sputum samples, which may indicate that a 
culture of one sputum sample is not homogeneous 
and not representative of the total bacillary popula-
tion in a patient. 
Our report shows that the absence of specifi c iden-
tifi cation of TB pathogens may have adverse conse-
quences for patient management. The rare possibility 
of co-infection with these two pathogens in TB pa-
tients should be stressed to increase the awareness of 
potential multi-infection, particularly in geographical 
areas where both pathogens are known to co-exist. 
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Figure Reverse dot blot hybridisation assay. Lanes 1–3: dif-
ferent sputum samples; Lane 4: positive control, H37Rv M. tu-
berculosis strain; Lane 5: clinical M. tuberculosis isolate 2; 
Lane 6: M. bovis BCG; Lane 7: clinical M. bovis isolate 1. Mc = 
M. tuberculosis complex-specific probe; Mb = M. bovis-specific 
probe; Mt = M. tuberculosis specific probes.
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Clinical experience of using clofazimine to 
treat multidrug-resistant tuberculosis 
Globally, the emergence of multidrug-resistant tuber-
culosis (MDR-TB) is threatening global health. Fa-
vorable clinical outcomes are restricted by limited 
drug availability, the high rate of drug toxicity and 
the long duration of treatment. 
Clofazimine was developed by Barry et al. in the 
1950s as an anti-tuberculosis drug.1 In vitro and in 
vivo trials in mice have recently demonstrated good 
activity against drug-resistant mycobacterial strains.2 
Some studies have reported favourable clinical out-
comes using clofazimine to treat MDR-TB;3–5 how-
ever, its clinical effi cacy and safety remain to be de-
termined. Here, we report our experience of using 
clofazimine in the treatment of MDR-TB. 
Between February 2005 and December 2011, 
32 patients were diagnosed with MDR-TB and 
treated with clofazimine-containing treatment regi-
mens. All isolates were resistant to ofl oxacin, and 
11 patients (34.4%) had extensively drug-resistant 
TB. The daily dosage of clofazimine was 150 mg. 
Treatment success was defi ned as both cure and treat-
ment completion. Of the 32 patients, 17 (53.1%) 
were men and the median age was 38 years (range 
20–70). The identifi ed isolates were resistant to a 
median of 9 drugs (range 4–13). Clofazimine was 
added to the treatment regimens for a median dura-
tion of 7 months (range 1–22). A median of four anti-
tuberculosis drugs (range 2–7), excluding clofazi-
mine, were administered over this period. Linezolid 
was administered to 15 patients, and 4 underwent 
surgical resection during the study period. 
Clofazimine was discontinued in 11 patients due to 
stock-outs and in another 9 patients due to adverse 
events. Culture conversion was achieved in 17 of the 
32 patients (53.1%). The median period from clofazi-
mine treatment to culture conversion was 14 weeks 
(range 2–21 weeks). At data censure (15 February 
2013), treatment outcomes were assessed in 31 pa-
tients, and 1 patient was still on a clofazimine-
c ontaining regimen after culture conversion. Treatment 
success was achieved in 15/31 patients (48.4%). Of 
the 15 successfully treated cases, 10 (66.7%) were 
treated with linezolid and 3 (20.0%) underwent sur-
gical resection. Only 4 patients achieved treatment 
success without linezolid or surgical resection. 
Skin discolouration developed in all patients. Four 
patients developed liver toxicity, and three developed 
gastrointestinal disturbance. Nine patients stopped 
receiving clofazimine due to adverse events, including 
skin discolouration (n = 3), hepatotoxicity (n = 3) 
and gastrointestinal disturbance (n = 3). 
We conducted logistic regression analysis to iden-
tify factors for the success of treatment. According to 
the univariate analysis, male sex and linezolid are sig-
nifi cant factors associated with treatment success. 
Multivariate analysis revealed that both male sex 
(odds ratio [OR] 16.67; 95% confi dence interval 
[CI] = 1.15–242.45; P = 0.039) and linezolid use 
(OR 142.41; 95%CI = 2.07–9784.93; P = 0.022) 
are signifi cant indicators of treatment success. 
Our results show that clofazimine may be an ef-
fective treatment for MDR-TB; however, concurrent 
or subsequent use of linezolid may contribute to treat-
ment success. 
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